Credit Suisse Group reissued their hold rating on shares of Henry Schein, Inc. (NASDAQ:HSIC) in a research note released on Thursday, July 13th. Credit Suisse Group currently has a $160.00 price target on the stock.
Other research analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Henry Schein from a hold rating to a buy rating and set a $190.00 target price on the stock in a research note on Tuesday, April 25th. Barrington Research boosted their target price on shares of Henry Schein from $196.00 to $198.00 and gave the company an outperform rating in a research note on Wednesday, May 10th. Stifel Nicolaus reissued a hold rating on shares of Henry Schein in a research report on Thursday, July 6th. Deutsche Bank AG started coverage on shares of Henry Schein in a research report on Wednesday, March 15th. They issued a hold rating and a $174.00 price target on the stock. Finally, Craig Hallum started coverage on shares of Henry Schein in a research report on Tuesday, April 11th. They issued a hold rating on the stock. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $185.56.
Henry Schein (HSIC) opened at 174.02 on Thursday. Henry Schein has a 12 month low of $146.23 and a 12 month high of $186.99. The firm has a market capitalization of $13.80 billion, a PE ratio of 26.45 and a beta of 1.09. The stock’s 50 day moving average price is $183.03 and its 200 day moving average price is $174.57.
Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 8th. The company reported $1.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.74 by $0.01. The firm had revenue of $3.06 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a net margin of 4.53% and a return on equity of 19.74%. The company’s quarterly revenue was up 6.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.64 earnings per share. Equities research analysts expect that Henry Schein will post $7.29 earnings per share for the current fiscal year.
In other news, EVP Gerald A. Benjamin sold 12,578 shares of the company’s stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $175.10, for a total value of $2,202,407.80. Following the completion of the sale, the executive vice president now owns 44,061 shares of the company’s stock, valued at approximately $7,715,081.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.27% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the stock. SpiderRock Advisors LLC purchased a new stake in shares of Henry Schein during the first quarter valued at $102,000. Lee Financial Co purchased a new stake in shares of Henry Schein during the second quarter valued at $161,000. Westside Investment Management Inc. purchased a new stake in shares of Henry Schein during the first quarter valued at $168,000. JNBA Financial Advisors purchased a new stake in shares of Henry Schein during the first quarter valued at $170,000. Finally, Peddock Capital Advisors LLC boosted its stake in shares of Henry Schein by 29.1% in the first quarter. Peddock Capital Advisors LLC now owns 1,097 shares of the company’s stock valued at $186,000 after buying an additional 247 shares during the last quarter. 90.87% of the stock is owned by institutional investors.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with our FREE daily email newsletter.